Paula O’Connor
Company: Nurix Therapeutics
Job title: Chief Medical Officer
Seminars:
Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader 9:00 am
Emerging clinical data support utility of novel MOA against validated target Activity demonstrated in the CNS and in patients harboring BTKi resistance mutationsRead more
day: Day Two AM